This article is more than 5 years old. Information may no longer be current.
Surgical resection extended OS in huge hepatocellular carcinoma
Patients with huge hepatocellular carcinoma who underwent surgical resection demonstrated superior OS compared with patients who underwent transarterial chemoembolization, according to study results.
The analysis included 351 patients with huge hepatocellular carcinoma — defined as ≥10 cm in diameter — who underwent first treatment between 2000 and 2009. Of them, 267 underwent transarterial chemoembolization (TACE) and 84 underwent surgical resection.
A higher percentage of patients who underwent surgery had a solitary tumor (72.6% vs. 39.3%; P˂.001) and unilobar tumor extent (77.4% vs. 50.9%; P˂.001). Patients in the surgery cohort also had less vessel invasion (29.8% vs. 51.3%; P˂.001).
Median follow-up was 10 months (range, 0-103).
Researchers reported higher OS rates at 1 year (73.8% vs. 37.8%), 3 years (54.8% vs. 16.3%) and 5 years (39.8% vs. 9.7%) in the surgical resection group (P˂.001).
The analysis included a propensity score-matched cohort consisting of 152 patients who were followed for a median of 14.5 months (range, 0-103). Results showed higher rates of OS at 1 year (69.7% vs. 40.2%), 2 years (58.6% vs. 33.9%) and 3 years (51.7% vs. 18.5%) among patients who underwent surgical resection (P˂.001).
Researchers also conducted multivariate analyses to identify independent prognostic factors associated with survival. They found male sex (HR=1.9; 95% CI, 1.01-3.58), albumin (HR=0.54; 95% CI, 0.34-0.85), ascites (HR=1.77; 95% CI, 1.02-3.08) and surgical resection (HR=0.44; 95% CI, 0.28-0.7) were linked to improved survival.
Disclosure: The researchers report no relevant financial disclosures.